Supreme Court PIL Seeks CBI Probe into Toxic Cough Syrup Deaths, Spotlights Regulatory Gaps

New Delhi – A series of tragic child deaths in Madhya Pradesh and Rajasthan, allegedly linked to the consumption of a contaminated cough syrup, has culminated in a Public Interest Litigation (PIL) before the Supreme Court, demanding a sweeping, court-monitored investigation and a comprehensive overhaul of India's drug safety framework. The petition thrusts the recurring issue of pharmaceutical contamination and regulatory failure into the highest judicial forum, raising critical questions about corporate accountability, the scope of medical liability, and the structural integrity of the nation's drug control apparatus.

The PIL, filed by advocate Vishal Tiwari, follows alarming reports of fatalities and severe kidney injuries among children who consumed 'Coldrif Cough Syrup', manufactured by the Tamil Nadu-based Sresan Pharma Pvt. Ltd. Preliminary investigations have revealed catastrophic levels of contamination with industrial solvents Diethylene Glycol (DEG) and Ethylene Glycol (EG). One lab report confirmed the presence of DEG at 48.6%, a staggering figure when the permissible limit is a mere 0.1%.

This legal challenge seeks to consolidate the fragmented response to the crisis, which has so far seen state-level bans, arrests, and official suspensions. It calls for the transfer of all related First Information Reports (FIRs) to the Central Bureau of Investigation (CBI) to ensure a unified and impartial probe under the supervision of a retired Supreme Court judge.

The Core Legal Arguments and Demands

At the heart of advocate Tiwari's petition is the argument that recurring incidents of lethal drug contamination point to deep-seated systemic failures that state-level inquiries are ill-equipped to address. The PIL proposes a two-pronged judicial intervention:

• A Coordinated Criminal Investigation: By seeking a CBI probe, the petitioner aims to overcome jurisdictional challenges and piece together a national picture of the manufacturing and distribution network that allowed the toxic syrup to reach consumers. This addresses concerns that isolated state investigations might fail to establish the full extent of culpability, from raw material sourcing to final batch approval.

• A National Judicial Commission: The plea advocates for the formation of a high-level National Judicial Commission or an Expert Committee, chaired by a retired Supreme Court judge. This body would be tasked with a broader mandate: to dissect the regulatory failures that enabled the tragedy and to recommend robust, preventative measures. As the petition suggests, such a committee should include experts in pharmacology, toxicology, and drug regulation to formulate a foolproof mechanism for the future. The petition states its goal is to have the commission "conduct a comprehensive inquiry into the manufacture, testing, and distribution of contaminated cough syrups containing Diethylene Glycol (DEG) and Ethylene Glycol (EG)."

The PIL also demands immediate practical relief, urging the court to direct a nationwide recall and seizure of all products from Sresan Pharma pending independent toxicological verification by NABL-accredited laboratories.

Criminal Liability and the Medical-Legal Quagmire

The case has exposed a sharp divide between legal enforcement and the medical community. In Chhindwara, Madhya Pradesh, police arrested Dr. Praveen Soni, a paediatrician who prescribed the syrup, and booked him alongside the manufacturer's directors under Section 105 (culpable homicide not amounting to murder) and Section 276 (adulteration of drugs) of the Bharatiya Nyaya Sanhita, as well as the Drugs and Cosmetics Act, 1940.

This action drew a swift and forceful rebuke from the Indian Medical Association (IMA), which condemned the doctor's arrest as an attempt to deflect blame from the real culprits. In a strongly worded statement, the IMA asserted, "The onus of the death of these hapless children falls squarely on the manufacturers and the authorities. Intimidation of the medical profession is uncalled for and will be resisted."

The IMA's position highlights a critical legal dilemma: a licensed medical practitioner prescribes a drug that has been approved for sale by regulatory bodies. The doctor, the association argues, has no means of detecting latent contamination at the point of prescription. The IMA's statement clarifies, "The prescribing doctor has no way of knowing whether a medicine is contaminated until adverse outcomes are reported among patients who have taken it."

The association has framed the issue as a clear case of a "spurious drug" under Section 17B of the Drugs and Cosmetics Act, arguing that the responsibility for quality control rests entirely with the manufacturer and the Central Drugs Standard Control Organisation (CDSCO). The arrest, according to the IMA, not only unfairly targets a medical professional but also dangerously misdirects the focus of the investigation away from the root cause of the tragedy.

Echoes of Past Failures and Regulatory Inertia

The current crisis does not exist in a vacuum. The IMA and other critics have pointed to a long history of similar incidents, both within India and involving Indian-made exports, most notably the 2022 deaths of children in Gambia linked to DEG and EG contamination.

The IMA invoked the landmark 2003 Mashelkar Committee Report, which identified systemic weaknesses plaguing India's drug regulatory system. The report highlighted "inadequate or weak drug control infrastructure at the State and Central level, inadequate testing facilities, shortage of drug inspectors, [and] non-uniformity of enforcement." The fact that these very issues are central to the current tragedy over two decades later suggests a profound and persistent failure to implement meaningful reforms.

The economic incentive for adulteration is stark. As the IMA explained, pharmaceutical-grade glycerin and propylene glycol are expensive. Unscrupulous manufacturers substitute them with cheap, industrial-grade DEG and EG, which are visually indistinguishable but lethally toxic, causing acute kidney failure and death, particularly in children.

Implications for the Legal and Regulatory Landscape

The Supreme Court's handling of this PIL will have far-reaching implications. A decision to order a court-monitored CBI probe could set a new precedent for handling cases of national public health crises, signalling a lack of faith in the capacity of state agencies to manage complex, multi-state corporate criminal investigations.

Furthermore, the potential formation of a National Judicial Commission could trigger the most significant review of the Drugs and Cosmetics Act and its enforcement since the Mashelkar Report. Legal experts will closely watch whether the Court's intervention leads to mandated reforms, such as:

• Mandatory Pre-Distribution Testing: The PIL calls for mandatory quality testing of all cough syrup batches for both domestic and export markets, a measure that could fundamentally alter industry practices.
• Real-Time Batch Monitoring: Strengthening CDSCO protocols to ensure real-time oversight of formulations containing potentially hazardous solvents like DEG and EG.
• Uniform Safety Audits: Establishing a standardized safety audit mechanism across all states to eliminate the "non-uniformity of enforcement" flagged by the Mashelkar Report.

As the case unfolds, it will serve as a critical test of India's legal framework to hold powerful pharmaceutical entities accountable and to protect its most vulnerable citizens. The outcome will determine whether this tragedy becomes another grim statistic or a catalyst for fundamental, life-saving reform in the country's drug safety regime.